FDA-Approved Medical Marijuana Clinical Trial for Epilepsy
A nationally renowned pediatric neurologist at Saint Barnabas has gotten FDA approval to study whether a cannabis-based drug could prevent seizures in children diagnosed with severe forms of epilepsy.
The development is sure to be watched closely in New Jersey, where a number of families whose children have Dravet syndrome, a potentially deadly form of epilepsy, say they cannot obtain yet a useful form of medicinal marijuana through the state Department of Health.
The U.S. Food and Drug Administration gave Orrin Devinsky, director of the University and Saint Barnabas Comprehensive Epilepsy Center, Roberta Cilio of the University of California – San Francisco’s Neurology Department, and GW Pharmaceuticals of the United Kingdom permission to use the experimental drug, Epidiolex, to treat 125 children with seizure disorders for whom traditional medicines have failed.
Enrollment in the trial will begin next month, Devinsky said.
“I think this is a big step forward in the science of Cannabidiods,” said Devinsky, referring to the spectrum of active ingredients in marijuana. “We will finally get some data on epilepsy, and this should provide the basis to plan a randomized double-blind study.”
The drug is a liquid form of pure cannabidiol, a non-psychoactive component of the cannabis plant that according to anecdotal reports has shown to reduce the frequency and intensity of seizures in children. The FDA’s Nov. 15th approval also gives Epidiolex “orphan drug” status, providing GW full marketing rights to be the lone producer of the product for seven years, the company said in a statement.
Orphan diseases are rare, occurring in less than 200,000 of people in the nation. There are 5,440 documented cases of Dravet syndrome in the United States and 6,710 in Europe, although the actual number may be higher because the condition is under-diagnosed, according to a statement from the pharmaceutical company. The seizures can damage the brain, delay development and cause lifelong intellectual disabilities.
Meghan and Brian Wilson of Scotch Plains, who have fought a very public battle to obtain medicinal marijuana for their 2-1/2-year-old daughter Vivian, said they are eager to see the drug trial get underway. But Vivian will not be enrolled next month out of concern for her fragile health.
Based on the experiences of other families whose children have Dravet, the children who were weaned off the anti-seizure drug Benzodiazepine — a tranquilizer that prevents or stops seizures by slowing down the central nervous system — saw the most benefits from cannabidiol. Cutting back on the “Benzo,” even very slowly, has triggered many severe seizures, Vivian’s mother said.
“I think it’s a great step in the direction of valid scientific research with cannabis,” she said. “I’d like to see the data before we add on another pharmaceutical, because at the end of the day it is a another pharmaceutical.
These are the first trials in human for this particular compound.
Brian Wilson said getting Vivian into the trial would take a “hard core withdrawal” from the Benzo. “I’d hate to expose Vivian to that until we know it will work.”
Parents whose children have Dravet, Lennox-Gastaut syndrome and other serious seizure disorders, say they are eager to try cannabidiol produced by growers in Colorado that has helped reduce seizure activity in more than 100 children. But none of the three medical marijuana dispensaries in New Jersey — including one that opened Wednesday and another Oct. 28 – carry the strains of pot that have shown any promise. No one has submitted a proposal approved by the state to produce a pot-infused edible product, which under state law are available for children.
The Wilsons purchased marijuana from Compassionate Care Foundation, Inc.in Egg Harbor, cooked it down into an oil, but cannot find a lab in the state willing to test its potency.
GW already has a track record producing marijuana-based medicine. Savitex, a cannabis-based spray used to treat muscle spasticity for patients with multiple sclerosis, is available in 22 countries. It is under FDA review.
“Through its efforts, GW aims to provide the necessary evidence to confirm the promise of CBD in epilepsy and ultimately enabling children to have access to an FDA-approved prescription,” according to a statement from Stephen Wright, GW’s research and development director.
November is National Epilepsy Awareness Month!
The evidence for the efficacy of cannabis in the treatment of epilepsy is overwhelming. Dr. Margaret Gedde has studied the effects of cannabis on various forms of epilepsy such as Dravet syndrome, Doose syndrome, Lennox-Gastaut syndrome, metachromatic leukodystrophy, cortical dysplasia, and idiopathic epilepsy. Dr. Gedde employed a compound of cannabis known as cannabidiol (CBD) in her studies, and each patient saw improvement where traditional treatments had failed. The results were dramatic. Eight out of 11 patients saw a 98-100% reduction in seizures. One patients saw a 75% reduction, and two reported a 20-24% reduction.
In another recent study, the NYU School of Medicine, in conjunction with the director of the NYU Comprehensive Epilepsy Center, published a report on a trial sponsored by GW Pharmaceuticals. The study is imperative for GW Pharmaceuticals, as they are attempting to pass the FDA approval process for a new drug called Epidiolex – a liquid form of pure CBD – in order to treat epilepsy.
To test the effectiveness of CBD on epilepsy patients, they sponsored the NYU study of 137 Dravet and Lennox-Gastaut patients during a 12 week period. The patients in the study had been previously unresponsive to epilepsy medications that only succeeded in producing side-effects such as drowsiness, diarrhea, decreased appetite, and fatigue. Like Dr. Gedde’s patients, the subjects in this study experienced dramatic improvement. Dravet patients saw an average 53% decrease in seizures, and Lennox-Gastaut patients experienced an average 55% decrease.
Because of the DEA’s Schedule I classification of cannabis (which ironically puts it in a category classified as having no currently accepted medical treatment use in the U.S.), it has been challenging to do extensive testing. In the place of laboratory studies, there are hundreds of personal anecdotes about the effectiveness of cannabis in the treatment of epilepsy.
Medical cannabis has been used to treat neurological conditions, such as epilepsy, for years – often with dramatic effective results, and garnered worldwide attention in 2013 after the mainstream media focused on the remarkable story of Charlotte Figi: a child with a severe form of epilepsy known as Dravet Syndrome. At the age of 5, Charlotte was having nearly 300 seizures per day, and her family had been told there were no other treatment options that could help her any further. The family turned to cannabinoid therapy, giving her cannabis oil twice a day. Charlotte is now 8 years old and continues to thrive, with seizures happening only 2 to 3 times per month.
John Malanca, founder of United Patients Group commented “What Charlotte’s story did was give a worldwide platform to the truth behind the efficacy of medical cannabis for devastating conditions such as epilepsy. We are excited to lend our support and to help further enlighten the epilepsy community and others on the truth behind medical cannabis.”
During UPG’s Medical Cannabis Conference held in May of 2016, they featured a speaker who had a very personal experience with epilepsy, and braved the stigma and outright backlash to treat her two children – one with epilepsy and the other with autism. Rebecca Gonzalez is a mother who advocates strongly for medical marijuana and for the use of full plant cannabis extract for treating her children and others like them. Her story is can be seen in this interview we did with Rebecca following our conference here.
Continuing the fight for access to medical marijuana
To address the severe need for an effective epilepsy treatment, GW Pharmaceuticals is continuing their trials of Epidiolex. In 2015, the company launched their third round of trials that will test 150 patients during a period of 14 weeks in a Epidiolex vs placebo study. This is just another step in order to get approval from the FDA for the cannabidiol-based drug.
But with the Schedule I classification of cannabis still in place, this may be difficult. And parents such as Rebecca Gonzalez and others don’t have time to wait. Perhaps the most unfortunate aspect of the ban on medicinal marijuana at the federal level is that, with so few studies, dosing and prescribing cannabis is not yet an exact science. Many families must undergo a trial and error process to discover the correct administration, strain, and dosage. And just like with traditional medication, each treatment must be tailored to each patient, since every patient is unique in their medical needs.
However, Bonni Goldstein, MD, who is the director of Canna-Centers and a UPG Advisory Board member, prescribes CBD to children with epilepsy and suggests that there is little to lose and much to gain when trying CBD. Unlike traditional pharmaceuticals, cannabis has fewer and less severe side-effects. She notes that cannabis can have side effects of drowsiness and fatigue, but that traditional epilepsy medications sometimes come with more severe symptoms such as liver failure, vomiting, etc. She even goes so far as to say that the side effects of CBD are less severe than those of epilepsy itself.
This week, United Patients Group, along with the Utah Association for Responsible Cannabis Legislation will host an evening of information, education and awareness for lawmakers, healthcare providers, public safety officials and others at the University of Utah to focus on the science of cannabinoid medicine and how its positive effects can improve the health of Utahans. Dr. Goldstein will be one of several featured speakers who will address how cannabis has had a profound and positive effect on treating patients who suffer from epilepsy among other chronic conditions such as Autism, Alzheimer’s and opioid addiction.
Celebrating National Epilepsy Awareness Month
As supporters of cannabis in the treatment of epilepsy and educators on the medical benefits of cannabis for various illnesses, we at United Patients Group are proud to participate in National Epilepsy Awareness Month. We will continue to battle epilepsy with knowledge, science, and support of the most effective treatments available.
Epilepsy Information: Epilepsy and Medical Marijuana Treatments
Epilepsy is a brain disorder that causes people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness.
There is a wealth of new scientific understanding regarding how medical marijuana or cannabis can be beneficial for treating Epilepsy.
Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy.
Tuesday, Sept. 30, 2003
RICHMOND, Va. – Ingredients in marijuana and the cannabinoid receptor protein produced naturally in the body to regulate the central nervous system and other bodily functions play a critical role in controlling spontaneous seizures in epilepsy, according to a new study by researchers at Virginia Commonwealth University.
The study, the first to look at marijuana and the brain’s cannabinoid system in live animals with spontaneous, recurrent seizures, suggests new avenues that researchers can explore in their search for more-effective drugs to treat epileptic patients who don’t respond to today’s anticonvulsant medications or surgery.
The results appear in the Oct. 1 issue of the Journal of Pharmacology and Experimental Therapeutics.
“Although marijuana is illegal in the United States, individuals both here and abroad report that marijuana has been therapeutic for them in the treatment of a variety of ailments, including epilepsy,” says Dr. Robert J. DeLorenzo, professor of neurology in the VCU School of Medicine.
“But the psychoactive side effects of marijuana make its use impractical in the treatment of epilepsy,” said DeLorenzo, who was the lead author on the article. “If we can understand how marijuana works to end seizures, we may be able to develop novel drugs that might do a better job of treating epileptic seizures.”
Epilepsy is one of the most common neurological conditions, characterized by spontaneously recurrent seizures. Approximately 1 percent of Americans have epilepsy, and 30 percent of those patients are resistant to conventional anticonvulsant drug treatments. Cannabinoids have been used as a natural remedy for seizures for thousands of years, and studies since at least 1974 have found that the primary psychoactive compound in marijuana displays anticonvulsant properties.
DeLorenzo and his colleagues in the VCU Department of Neurology and the Department of Pharmacology and Toxicology have been studying the therapeutic effects of marijuana on epilepsy and other illnesses for more than a decade. They were the first three years ago to show that cannabinoids work at controlling seizures by activating a protein known as the CB1 receptor that is found in the memory-related area of the brain, the nervous system and other tissues and organs in the body. Research has shown that the CB1 receptor is responsible for the psychoactive effects of marijuana. It also is responsible for controlling excitability and regulating relaxation.
The current study was designed to evaluate the role of the CB1 receptor and function of the body’s cannabinoid system in regulating seizures.
The team injected chronically epileptic rats with different combinations of six drugs: 1) an extract of marijuana, 2) two synthetic drugs that include the key psychoactive ingredients in marijuana, 3) the common anticonvulsant drugs Phenobarbital and phenytoin and 4) a drug to block the activation of the CB1 receptor by cannabinoids in the brain. The marijuana extract and synthetic marijuana drugs completely eliminated the rats’ seizures, which averaged three over a 10-hour period. The Phenobarbital and phenytoin failed to completely eliminate the seizures. Injection of the CB1 antagonist significantly increased the both the duration and frequency of seizures, in some cases to a level consistent with a severe, prolonged form of epilepsy known as status epilepticus.
“This study indicates that cannabinoids may offer unique advantages in treating seizures compared with currently prescribed anticonvulsants,” DeLorenzo said. “It shows not only the anticonvulsant activity of exogenously applied cannabinoids but also suggests that the brain’s cannabinoid system works to limit seizure duration by activating the CB1 receptor. Understanding the factors that contribute to seizure initiation and termination has important implications for our ability to treat epilepsy and for the potential development of novel anticonvulsant agents.”
DeLorenzo’s team is now assessing the dosage requirements and evaluating the long-term effects of using cannabinoids for epilepsy in animals.
Endocannabinoids and Their Implications for Epilepsy
This review covers the main features of a newly discovered intercellular signaling system in which endogenous ligands of the brain’s cannabinoid receptors, or endocannabinoids, serve as retrograde messengers that enable a cell to control the strength of its own synaptic inputs. Endocannabinoids are released by bursts of action potentials, including events resembling interictal spikes, and probably by seizures as well. Activation of cannabinoid receptors has been implicated in neuroprotection against excitotoxicity and can help explain the anticonvulsant properties of cannabinoids that have been known since antiquity.
Cannabis in its various forms, including marijuana and hashish, is produced from the flowers and leaves of the hemp plant, Cannabis sativa. Through their primary psychoactive ingredient, Δ9-tetrahydrocannabinol (THC), these drugs affect the central nervous system by activating specific membrane-bound receptors (1). The primary brain receptors, cannabinoid receptors type 1 (CB1), are G protein–coupled, seven-transmembrane domain proteins that share numerous similarities with heterotrimeric G protein–coupled receptors for conventional neurotransmitters such as γ-aminobutyric acid (GABA) and glutamate. The CB1s bind THC with a high degree of selectivity and are heterogeneously distributed throughout the brain. Inasmuch as THC is a plant-derived compound not produced in mammals, endogenous ligands must exist for the cannabinoid receptor, that is, endocannabinoids. Indeed, several endogenous ligands for CB1 have been discovered (2,3), with anandamide being the first (4). Anandamide and 2-arachidonoyl glycerol (2-AG), are thought to be the major brain endocannabinoids, with regional differences in which one or the other predominates. Endocannabinoids have been strongly implicated in a growing variety of physiologic phenomena, including regulation of eating (5), anxiety (6), pain (7), extinction of aversive memories (8), and neuroprotection (9). Potent agonists and antagonists (10) for CB1 exist and may serve as the foundation of new therapeutic strategies for treating pathologies. The voluminous work summarized here has been extensively covered in recent reviews on cannabinoid neurochemistry and pharmacology (3,11–14) as well as neurophysiology (15–19). This review focuses on the neurophysiology of the endocannabinoid systems.
Neurophysiological Properties of the Endocannabinoids Systems
Anandamide and 2-AG are small fatty acid derivatives of arachidonic acid that are synthesized primarily by cleavage from membrane phospholipids by lipases. Unlike conventional neurotransmitters, they are not stored in or released from vesicles but rather are produced inside cells when neuronal activity triggers the enzymes. How they gain access to the extracellular environment is not understood, yet clearly, they get out and reach their target CB1 receptors on other cells. They may diffuse through the membranes of the originating cells or be transported across them.
Synthesis and release of anandamide and 2-AG can be initiated by an increase in intracellular neuronal calcium concentration. Important variables, therefore, include the factors that cause intracellular calcium to increase and the magnitude and kinetics of the related processes. A single action potential does not admit enough calcium for endocannabinoid production, but action-potential bursts do. The duration of endocannabinoid actions is limited by cellular uptake and enzymatic degradation. A transporter operating by facilitated diffusion returns both anandamide and 2-AG to the interior of cells where the degradative enzymes, fatty-acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), degrade them. Whereas neither FAAH (3) nor MGL (20) is strongly selective in cell-free systems, in intact cells, FAAH selectively degrades anandamide, and MGL preferentially affects 2-AG. In addition, FAAH is found predominantly in postsynaptic cell somata and dendrites (21), whereas MGL is in presynaptic nerve terminals (20). These factors may make possible therapeutic strategies for targeting one or the other ligand. For example, FAAH knockout mice are more susceptible to endocannabinoid-induced seizures (22), implying an involvement of anandamide that could be exploited.
Endocannabinoids as Retrograde Messengers
When do cells release endocannabinoids and how is this detected? Much of the information reviewed here was gathered during electrophysiological studies of synaptic transmission using in vitro brain slices. In the early 1990s, it was discovered that depolarization, for a second or so, of a single pyramidal cell or Purkinje cell in rodent hippocampal (23) and cerebellar slices (24) was followed by transient suppression of the incoming GABA-mediated inhibitory synaptic currents. This phenomenon was named depolarization-induced suppression of inhibition (DSI). Although DSI, in principle, could have been caused by a reduced sensitivity of the postsynaptic GABA receptors, detailed quantal analyses showed that GABA-receptor sensitivity was unchanged. Instead, DSI caused a decrease in GABA release from the interneurons. As it is induced in the pyramidal cell, yet expressed as a decrease in GABA release, DSI represents a retrograde form of synaptic signaling (see Fig. 1 for a schematic illustration). Numerous features of DSI and the entirely analogous depolarization-induced suppression of excitation (DSE) were unraveled, but the retrograde messenger between the pyramidal cell and the interneurons remained elusive. In 2001, the problem was solved when two groups showed that an endocannabinoid is the messenger in DSI (25,26), and a third showed that, in the cerebellum, it is the messenger in DSE (27). Agonists of CB1 mimicked or occluded and antagonists of CB1 blocked these phenomena, whereas mice lacking CB1 had no DSI (28,29).
The Inhibitory Actions of Endocannabinoids
What do endocannabinoids do? They inhibit neurotransmitter release from nerve terminals that synapse on the endocannabinoid-generating cell. The localization of the CB1s is obviously the key to this interpretation and to understanding the functions of endocannabinoid systems. In neocortex, hippocampus, and amygdala, for instance, immunocytochemical methods show that CB1s are found overwhelmingly on the nerve terminals of a distinct group of GABAergic interneurons, which besides GABA, also contain the neuropeptide cholecystokinin (CCK) (19). In the cerebellum and striatum, in contrast, CB1s are found in high concentration on the terminals of the excitatory glutamatergic fiber systems. Thus depending on the brain region, endocannabinoids can regulate the release of GABA (and CCK) or glutamate.
Activation of presynaptic CB1s causes presynaptic inhibition of transmitter release. Generally, a major mechanism of synaptic inhibition is the suppression of presynaptic voltage-gated calcium channels, and exogenous cannabinoids do block calcium currents (30–32). In hippocampus and cerebellum, endocannabinoids appear to reduce the calcium influx necessary for release. Imaging of calcium concentrations in cerebellar climbing fiber terminals directly reveals the reduction in calcium influx associated with DSE (27). Additional mechanisms for DSI and DSE expression include an increase in presynaptic potassium channel activity (33), which would impede action-potential invasion into synaptic boutons and interference with the vesicular release machinery (34,35). In all cases, CB1 activation reduces transmitter release.
During DSI and DSE, the suppression of synaptic transmission is transient, lasting seconds. What neurophysiologic functions are served? DSI can facilitate induction of long-term potentiation (LTP). The strength of GABAergic inhibition usually regulates the ability of excitatory synapses to induce LTP—strong inhibition prevents opening of the N-methyl-d-aspartate (NMDA) receptors that is required for LTP induction. Synaptic potentials normally too weak to induce LTP can do so when inhibition is pharmacologically blocked. DSI is a transient form of disinhibition, and indeed, weak excitatory potentials that occur during DSI induce LTP (36). LTP did not occur if CB1s were blocked. Hence, endocannabinoids can regulate synaptic plasticity. They also can modulate rhythmic firing patterns. High frequency (∼40 Hz, gamma) rhythms, such as detected by EEG, are strongly reduced by exogenous cannabinoids (37). The slower (4–14 Hz) theta rhythms prevalent in the hippocampus during various behavioral states also are affected by cannabinoids. Recently, a novel form of theta rhythm, generated by an interneuronal network within the hippocampus, was found to be transiently interrupted by DSI (Reich, Carson, and Alger, unpublished data, 2004). DSE probably serves analogous functions.
Calcium-dependent Production of Endocannabinoids
It might appear that endocannabinoid release is a restricted phenomenon, tied to specific conditions of intracellular calcium increase. Actually, endocannabinoids can be released under a wide variety of circumstances because their production does not require activation of voltage-gated calcium channels and, evidently, is not even calcium dependent. Additional endocannabinoid actions first were suggested by the observation that activation of striatal D2 dopamine receptors selectively elevated anandamide levels (2-AG was not affected). Anandamide mitigated the behavioral hyperactivity that was induced by the direct actions of dopamine (38).
Two other classes of G protein–coupled receptors can induce endocannabinoid production and release: (a) the group I class of metabotropic glutamate receptors (mGluRs) in principal cells in the cerebellum (39) and hippocampus (28), and (b) activation of muscarinic acetylcholine receptors (mAChRs) in the hippocampus (40). The mGluR and mAChR pathways seem distinct from the calcium-dependent pathway of endocannabinoid production. Preventing increases in intracellular calcium with high concentrations of calcium chelators has no effect on G protein–induced endocannabinoid production, and measurements of intracellular calcium reveal no increase in calcium concentration associated with the activation of the mGluR and mAChR receptors. Injection of GTPγS, a strong activator of G proteins, causes persistent release of endocannabinoid in the absence of any other form of activation of the cell (40). Two major reasons exist for emphasizing endocannabinoid release by mGluRs and mAChRs. First, they are components of prominent neurotransmitter systems that mediate numerous neurophysiological and behavioral effects. A new understanding of these transmitter systems will result if endocannabinoids are the proximate mediators of these effects. Second, it implies that endocannabinoids have a much broader scope of action than initially imagined.
Different Modes of Endocannabinoid Release Have Different Functions
Are the endocannabinoids released by the G protein–coupled and calcium-dependent pathways the same; and do they subserve the same neurophysiologic functions? As noted, in areas of the brain studied thus far, 2-AG and anandamide are favored as the major endocannabinoid candidates. Nevertheless, the evidence is not conclusive, and questions, such as whether different biosynthetic pathways release different endocannabinoids, currently cannot be answered. Data increasingly point to more than one synthetic pathway producing more than one type of physiologic effect. The G protein–dependent pathway can enhance DSI (i.e., calcium-dependent endocannabinoid release) (28,40), although an effect of DSI on the G protein–dependent pathway has not been described. Inhibitors of phospholipase C and diacylglycerol lipase inhibit some G protein pathways without affecting DSI, implying further distinctions between the two modes of endocannabinoid biosynthesis.
Persistent release of endocannabinoids will not occur during brief periods of synaptic transmission, and stronger neuronal stimulation, such as epileptic seizure, is probably required. The consequences of prolonged endocannabinoid release will undoubtedly be different from brief, transient release. DSI and DSE are transient phenomena—the effects of the endocannabinoids are readily reversed when CB1 activation ceases. However, G protein–dependent endocannabinoid release can lead to lasting synaptic depression of inhibitory synapses (41). LTD of inhibitory synapses has been called iLTD and is caused by minutes-long activation of mGluRs. Blocking either mGluRs or CB1s does not alter iLTD maintenance, even though earlier blockade of either receptor prevents iLTD initiation. Several short bursts of synaptic glutamate stimulation can release endocannabinoids for several minutes, and it was proposed that the duration of endocannabinoid release was sufficient to convert the normally reversible synaptic suppression into iLTD (41). A caveat is that these results were obtained at room temperature and the duration of endocannabinoid actions are very temperature sensitive. It is not yet clear if synaptic stimulation would cause such prolonged release at physiologic temperatures. In any event, iLTD induction requires more than simply prolonged activation of CB1, because an equivalent release of endocannabinoids caused by mAChR activation does not induce iLTD (Kim and Alger, unpublished data, 2004).
Pathologic long-term remodeling of the endocannabinoid system also may occur. Developmental febrile seizures can increase endocannabinoid-mediated suppression of synaptic GABA release (42) by upregulating the number of presynaptic CB1 receptors on the GABAergic interneurons. The ultimate effect on the young brain is not clear, although greater susceptibility to disinhibition could be a destabilizing influence.
From what is known about their synthesis and release, endocannabinoids should be produced under many conditions of increased neuronal excitability and specific intercellular signaling. For example, an epileptic seizure, with its large swings in transmembrane voltage, increases in intracellular calcium, and marked release of neurotransmitters, such as acetylcholine and glutamate, should prominently release endocannabinoids. Indeed, seizures induced by kainic acid (a glutamate agonist) increase hippocampal levels of anandamide in normal and wild-type mice (9). Intriguingly, CB1 knockout mice and normal mice treated with a CB1 antagonist had more pronounced seizures and more severe excitotoxic cell death than untreated normal mice. Although the detailed mechanisms of neuroprotection have not been worked out, the rapid increases in expression of the immediate early genes, c-fos and zipf268, and subsequent increase in brain-derived neurotrophic factor (BDNF) normally induced by kainic acid, were absent in the CB1 knockout mice. The results complement previous evidence that exogenous cannabinoids can be neuroprotective and show that CB1 activation by seizure-induced release of endocannabinoids also is normally neuroprotective.
The important new directions being opened by investigations of endocannabinoids underscore the prescient opinion of Robert Christison (43), who, in 1848, noting its various beneficial effects, argued that cannabis “is a remedy which deserves a more extensive inquiry…”